Drilldown: Medicines
Use the filters below to narrow your results.
generic:
None (1) ·
2-FDCK (1) ·
3-HO-PCE (1) ·
3-HO-PCP (1) ·
3-MeO-PCE (1) ·
3-MeO-PCP (1) ·
4-FA (1) ·
4-MeO-PCP (1) ·
5-APB (1) ·
5-MAPB (1) ·
6-APB (1) ·
6-APDB (1) ·
Butylone (1) ·
Deschloroketamine (1) ·
Dextromethorphan (1) ·
Dextrorphan (1) ·
Diphenidine (1) ·
Ephenidine (1) ·
Ephylone (1) ·
Ethylone (1) ·
Eticyclidine (1) ·
Ibogaine (1) ·
MDA (1) ·
MDAI (1) ·
MDEA (1) ·
MDMA (1) ·
Mephedrone (1) ·
Methoxetamine (1) ·
Methylone (1) ·
Nitrous oxide (1) ·
O-PCE (1) ·
Olanzapine / Fluoxetine (1) ·
PMA (1) ·
PMMA (1) ·
Salvia divinorum (1) ·
Salvinorin A (1) ·
Xenon (1)
brand:
classes: (Click arrow to add another value)
mechanism:
None (1) ·
Active metabolite of DXM; NMDA antagonist (1) ·
Contains salvinorin A (1) ·
Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) ·
Kappa-opioid receptor agonist (1) ·
MAO inhibitor; monoamine releasing agent (1) ·
MAO inhibitor; serotonin releasing agent (1) ·
Monoamine releasing agent (3) ·
Monoamine releasing agent; 5-HT2A agonist (1) ·
Monoamine releasing agent; serotonergic at higher doses (1) ·
NMDA antagonist (3) ·
NMDA antagonist; endogenous opioid releaser (1) ·
NMDA antagonist; fluorinated ketamine analogue (1) ·
NMDA antagonist; kappa-opioid agonist (1) ·
NMDA antagonist; ketamine analogue (1) ·
NMDA antagonist; more stimulating than PCP (1) ·
NMDA antagonist; opioid agonist (1) ·
NMDA antagonist; potent opioid agonist (1) ·
NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) ·
NMDA antagonist; sigma receptor agonist (2) ·
NMDA antagonist; sigma receptor agonist; dopaminergic (1) ·
NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) ·
Serotonin releasing agent (2) ·
Serotonin releasing agent; 5-HT2A agonist (3) ·
Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) ·
Serotonin/norepinephrine/dopamine releasing agent (3) ·
'"`UNIQ--vote-00001549-QINU`"' Metabolic effects (weight gain, dyslipidemia, glucose dysregulation) dominate the long-term tolerability profile; routine metabolic monitoring is standard'"`UNIQ--ref-0000154A-QINU`"'. (1)
uses:
None (35) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) ·
'"`UNIQ--vote-0000154B-QINU`"', '"`UNIQ--vote-0000154C-QINU`"' (1)
starting dose:
None (35) ·
6/25 mg PO once daily in the evening; titrate within range 3/25 to 18/75 mg by clinical response and tolerability (1) ·
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
onset:
duration:
halflife:
bioavailability:
pregnancy:
legal:
None (35) ·
Rx, Schedule III (US). REMS program required. (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the '''antidepressant Boxed Warning''' for suicidality in children/adolescents/young adults and the atypical-neuroleptic '''Boxed Warning''' for increased mortality in elderly dementia patients'"`UNIQ--ref-0000154F-QINU`"' (1)
Showing below up to 37 results in range #1 to #37.